ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "a8a5c70f-90f1-404f-b1a9-98fa220fc100"}, "_deposit": {"id": "23914", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "23914"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00023914", "sets": ["501"]}, "author_link": ["70998", "70999", "71000", "71001", "71002", "71003"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageEnd": "1404", "bibliographicPageStart": "1393", "bibliographicVolumeNumber": "8", "bibliographic_titles": [{"bibliographic_title": "Immunotherapy", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.2217/imt-2016-0076"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/26117"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Future Medicine", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.2217/imt-2016-0076", "subitem_relation_type_select": "DOI"}}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1750-743X", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kuramitsu, Shunichiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamichi, Akane", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohka, Fumiharu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motomura, Kazuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hara, Masahito", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Natsume, Atsushi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "71003", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "0815Review_Figures.pdf", "filesize": [{"value": "334.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 334700.0, "url": {"label": "0815Review_Figures.pdf ファイル公開:2017/12/01", "objectType": "dataset", "url": "https://nagoya.repo.nii.ac.jp/record/23914/files/0815Review_Figures.pdf"}, "version_id": "22838a25-7eec-4984-8ae0-2dbc6488fcdb"}, {"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 1, "filename": "20160815revision_kuramitsu_ACT_review_v11.pdf", "filesize": [{"value": "249.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 249600.0, "url": {"label": "20160815revision_kuramitsu_ACT_review_v11.pdf ファイル公開:2017/12/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/23914/files/20160815revision_kuramitsu_ACT_review_v11.pdf"}, "version_id": "c419b299-6256-494e-bfa9-070a7fa7583c"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/26117", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-04-21"}, "publish_date": "2017-04-21", "publish_status": "0", "recid": "23914", "relation": {}, "relation_version_is_last": true, "title": ["Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities

http://hdl.handle.net/2237/26117
http://hdl.handle.net/2237/26117
e0f80cc0-e8e6-4c3c-ba66-c8b0459a6e3c
名前 / ファイル ライセンス アクション
0815Review_Figures.pdf 0815Review_Figures.pdf ファイル公開:2017/12/01 (334.7 kB)
20160815revision_kuramitsu_ACT_review_v11.pdf 20160815revision_kuramitsu_ACT_review_v11.pdf ファイル公開:2017/12/01 (249.6 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-04-21
タイトル
タイトル Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities
言語 en
著者 Kuramitsu, Shunichiro

× Kuramitsu, Shunichiro

WEKO 70998

en Kuramitsu, Shunichiro

Search repository
Yamamichi, Akane

× Yamamichi, Akane

WEKO 70999

en Yamamichi, Akane

Search repository
Ohka, Fumiharu

× Ohka, Fumiharu

WEKO 71000

en Ohka, Fumiharu

Search repository
Motomura, Kazuya

× Motomura, Kazuya

WEKO 71001

en Motomura, Kazuya

Search repository
Hara, Masahito

× Hara, Masahito

WEKO 71002

en Hara, Masahito

Search repository
Natsume, Atsushi

× Natsume, Atsushi

WEKO 71003

en Natsume, Atsushi

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
抄録
内容記述 Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Future Medicine
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.2217/imt-2016-0076
ISSN
収録物識別子タイプ PISSN
収録物識別子 1750-743X
書誌情報 en : Immunotherapy

巻 8, 号 12, p. 1393-1404, 発行日 2016-12
著者版フラグ
値 author
URI
識別子 http://doi.org/10.2217/imt-2016-0076
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/26117
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:21:07.702994
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3